Key facts
- It has raised $4.3M; the latest was Early Stage VC in Mar 2026.
- Notable investors include Jiaxing Deshi Private Equity Fund Management, Qihang Capital, TigerYeah Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Juhai Hengchuang
- ·The full record, as it builds
Funding rounds
No funding rounds for Juhai Hengchuang are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Juhai Hengchuang
Manufacturer of medical devices and nucleic acid compounds intended for the detection and analysis of pharmaceutical substances. The company offers instrumentation for assessing pharmaceutical materials, along with associated manufacturing capabilities, technical functions, and operational characteristics that facilitate precise evaluation workflows for organizations engaged in medical research, product development, laboratory testing, and related analytical activities, enabling these groups to advance their investigative processes effectively.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Juhai Hengchuang doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Juhai Hengchuang shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Juhai Hengchuang in its N-PORT filings yet. We sweep new filings monthly.